The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Interim data from the phase I/II study on BNZ-1 in patients with refractory cutaneous T-cell lymphoma

Jul 24, 2020

On July 20, 2020, positive interim clinical data from the phase I/II study of BNZ-1 in patients with refractory cutaneous T-cell lymphoma (rCTCL) were announced.

BNZ-1 is a selective multi-cytokine inhibitor targeting interleukin (IL)-2, IL-9, and IL-15, which has demonstrated a favorable safety profile in two phase I studies in healthy volunteers. A phase I/II dose-escalation study ( NCT03239392 ) is currently investigating the safety and activity of BNZ-1 in patients with rCTCL.

Patients with rCTCL, who had failed standard of care and other available treatment options, were treated with BNZ-1 across four different doses of 0.5, 1, 2, and 4 mg/kg for intravenous weekly dosing. The primary endpoint was overall safety after 4 weeks. There was a 3-month treatment extension to further evaluate the safety and efficacy. BNZ-1 was well tolerated with no dose limiting toxicities. The 2 mg/kg cohort included 19 patients with rCTCL, who had failed a median of seven prior skin-directed and systemic therapies, and demonstrated a clinical response, with

• over 80% of patients showing some improvement in tumor burden, assessed by the modified severity-weighted assessment tool (mSWAT) score

• about half achieving a partial response in the mSWAT score, and 5% achieving a complete response

• a mean duration of response of 277 days (9.2 months) in responding patients at the time of the data cutoff

Based on the outcomes of the phase II study, a phase III study could start in the first half of 2021.

  1. Bioniz Therapeutics. Bioniz announces positive efficacy and safety data for BNZ-1 from interim analysis of phase 1/2 study in cutaneous T-cell lymphoma. https://bioniz.com/bioniz-announces-positive-efficacy-and-safety-data-for-bnz-1-from-interim-analysis-of-phase-1-2-study-in-cutaneous-t-cell-lymphoma/. Published Jul 20, 2020. Accessed Jul 22, 2020.